- Without admitting wrongdoing, Pfizer (PFE +0.3%) agrees to pay $325M to certain third party payers to settle allegations that it defrauded insurers and other healthcare benefit providers by marketing Neurotonin for unapproved uses.
- On April 21, the company agreed to pay $190M to settle litigation in New Jersey. The case was brought by Neurotonin buyers who accused it of taking steps to keep cheaper generic versions of the drug off the market.
- In May 2004 PFE agreed to pay $430M and plead guilty to criminal charges for illegally marketing Neurotonin for unapproved uses.
- The company acquired Neurotonin when in bought Warner-Lambert in 2000.
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Pages
▼
No comments:
Post a Comment